CHMP rekommenderar godkännande av Xadago(safinamide) för behandling av Parkinsons sjukdom

Newron Pharmaceuticals S.p.A. (”Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve the use of Xadago(TM) (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ’Standard of Care’.

To view the Multimedia News Release, please click:
http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons